Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.60 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.60 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.49 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.49 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7060157 | 1.00 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL5249703 | 1.00 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL7063456 | 1.00 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL10561321 | 1.00 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL103054 | 1.00 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL2417250 | 1.00 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL25266425 | 1.00 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL15016340 | 1.00 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL7058701 | 1.00 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL7063486 | 1.00 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071559-A | Methods and compositions for treating Rett syndrome | 亲神经剂生物科学有限公司 | 2018-12-21 | — | — | CN | claimed |
| CN-104382853-A | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MARINA BIOTECH INC | 2015-03-04 | — | — | CN | claimed |
| US-12473314-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4635481-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4218722-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4537828-A2 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4200301-B1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024251108-A1 | IONIZABLE LIPID COMPOUND, LIPID CARRIER COMPRISING SAME AND USE THEREOF | 北京因诺惟康医药科技有限公司 | 2024-12-12 | — | — | WO | disclosed |
| CN-118955699-A | Broadly neutralizing anti-HIV antibodies | 洛克菲勒大学 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024212958-A1 | IONIZABLE LIPID COMPOUND, LIPID CARRIER COMPRISING SAME, AND APPLICATION | 北京因诺惟康医药科技有限公司 | 2024-10-17 | — | — | WO | disclosed |
| WO-2024192906-A1 | LIPID COMPOUND FOR DELIVERING THERAPEUTIC AGENT, PREPARATION METHOD THEREFOR, AND USE THEREOF | 尧唐(上海)生物科技有限公司 | 2024-09-26 | — | — | WO | disclosed |
| US-20140294782-A1 | Reprogramming of Cellular Adhesion | US ARMY, SECRETARY OF THE ARMY | 2014-10-02 | — | — | US | disclosed |
| EP-2773327-A1 | REPROGRAMMING OF CELLULAR ADHESION | The Regents of The University of California (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8808703-B2 | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-08-19 | — | — | US | disclosed |
| WO-2013067203-A1 | REPROGRAMMING OF CELLULAR ADHESION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130065861-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2013-03-14 | — | — | US | disclosed |
| US-20110064794-A1 | Drug Delivery System, its Preparation Process and Use | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2011-03-17 | — | — | US | disclosed |
| US-20100297156-A1 | ANALOGUES OF PHOSPHATIDYLINOSITOL MANNOSIDES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2010-11-25 | — | — | US | disclosed |
| US-20100297156-A1 | ANALOGUES OF PHOSPHATIDYLINOSITOL MANNOSIDES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2010-11-25 | — | — | US | disclosed |
| US-4847376-A | COLORIMETRIC ANALYSIS | BOEHRINGER MANNHEIM GMBH (DE) | 1989-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065861-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | TLR2, TLR4, TLR3 | USP2 1960/4885LPAR1 81/4885LPAR3 68/4885 |
| US-20100297156-A1 | ANALOGUES OF PHOSPHATIDYLINOSITOL MANNOSIDES | PIK3CA, PIK3CB, PIK3CG | USP2 4005/4885LPAR1 515/4885LPAR3 401/4885 |
| US-12473314-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | USP2 4298/4885LPAR1 87/4885LPAR3 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.